The latest price target for Nuvation Bio (NYSE:NUVB) was reported by RBC Capital on May 5, 2026. The analyst firm set a price target for $20.00 expecting NUVB to rise to within 12 months (a possible 315.80% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for Nuvation Bio (NYSE:NUVB) was provided by RBC Capital, and Nuvation Bio reiterated their outperform rating.

The last upgrade for Nuvation Bio Inc happened on March 27, 2024 when Jefferies raised their price target to $10. Jefferies previously had a hold for Nuvation Bio Inc.

There is no last downgrade for Nuvation Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvation Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvation Bio was filed on May 5, 2026 so you should expect the next rating to be made available sometime around May 5, 2027.

While ratings are subjective and will change, the latest Nuvation Bio (NUVB) rating was a reiterated with a price target of $20.00 to $20.00. The current price Nuvation Bio (NUVB) is trading at is $4.81, which is out of the analyst’s predicted range.